RxDoctor Payments Data

Carrie Dylla, PA

Psychiatric/Mental Health · Watertown, SDNPI 1245274240

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 24.1% of the total. 2025 is the largest year on record at $1,516, 3.6 times the $423 reported in 2021. Among psychiatric/mental health clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,320in general payments, 2019–2025

Across 311 payments — averaging $13.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$532
  • Neurocrine Biosciences, Inc.$342
  • Johnson & Johnson$340
  • Otsuka America Pharmaceutical, Inc.$339
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$306
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,27399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,320 in reported general payments places this provider in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Medicare billing

Part B allowed, 2024
$27,327
Medicare patients
120
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil100$350,402
Invega SustennaPaliperidone Palmitate72$227,446
IngrezzaValbenazine Tosylate14$106,762
VraylarCariprazine Hcl82$105,858
Invega TrinzaPaliperidone Palmitate11$104,974
UzedyRisperidone16$64,534
LybalviOlanzapine/Samidorphan Malate34$51,710
FanaptIloperidone11$38,879
RexultiBrexpiprazole17$25,058
AuvelityDextromethorphan Hbr/Bupropion20$21,993
TrintellixVortioxetine Hydrobromide35$18,915
Clozapine353$18,748
Lurasidone Hcl120$14,714
Vilazodone Hcl76$9,055
BelsomraSuvorexant19$8,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada, Lybalvi$532$402,112134 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$340$332,42083 claims
AbbVieVraylar, Fetzima$1,043$113,23798 claims
Neurocrine Biosciences, Inc.Ingrezza$342$106,76214 claims
Teva Pharmaceuticals USA, Inc.Uzedy$272$64,53416 claims
Vanda Pharmaceuticals Inc.Fanapt$176$38,87911 claims
Otsuka America Pharmaceutical, Inc.Rexulti$339$25,05817 claims
Axsome Therapeutics, Inc.Auvelity$142$21,99320 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$109$18,91535 claims
Idorsia Pharmaceuticals US IncQuviviq$28$7,23016 claims
Ironshore Pharmaceuticals Inc.Jornay Pm$13$5,35013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Watertown

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →